Detail akcie Incyte online

Business Summary: Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonists targeting Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Incyte Corp revenues increased 9% to $880.9M. Net income increased from $21.7M to $169.5M. Revenues reflect OPZELURA revenues segment increase of 52% to $85.7M, Milestone and contract revenues segment increase from $0K to $25M. Net income benefited from Unrealized gain (loss) on long term inve increase from $5.3M (expense) to $99.9M (income), Selling & General Expenses decrease of 12% to $194.7M (expense).